Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00358189
Other study ID # B4061I
Secondary ID
Status Completed
Phase N/A
First received July 28, 2006
Last updated February 3, 2009
Start date October 2006
Est. completion date May 2008

Study information

Verified date July 2006
Source VA Office of Research and Development
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Observational

Clinical Trial Summary

The purpose of this study is to assess the effects of unilateral deep brain stimulation on upper and lower extremity motor function in advanced Parkinson's disease patients. It is hypothesized the unilateral stimulation will lead to improvements in bilateral motor functioning.


Description:

Parkinson's disease (PD) is a chronic progressive degenerative illness in which dopaminergic neurons in the substantia nigra pars compacta deteriorate resulting in a reduction in striatal dopamine. Decreased levels of dopamine in PD patients results in varying combinations of akinesia, bradykinesia, tremor, rigidity and gait\postural instability. Parkinson's disease is the second most common neurodegenerative disorder, affecting nearly 1.2 million Americans with annual treatment costs approaching $25 billion. Deep brain stimulation (DBS) is a surgical approach developed for the treatment of advanced PD that provides promise in alleviating its motor deficits. The most common stimulation site for the treatment of advanced PD is the subthalamic nucleus (STN). Nearly 90 percent of patients involved in a multi-center trial with STN stimulation underwent single session bilateral implantation. It is generally accepted that bilateral STN stimulation improves upper and lower extremity function. However, bilateral STN stimulation may be associated with postoperative morbidity including cognitive deficits and neuropsychiatric changes. In contrast, the effects of unilateral STN stimulation on bilateral upper and lower extremity motor function are poorly understood. The question of whether to proceed with bilateral or unilateral surgery is important, as a significant number of patients for whom surgery is a consideration have relative contraindications such as age greater than 70, cognitive decline, or other medical conditions that may prevent bilateral implantation. Considering the risks for bilateral implantation may be greater than unilateral procedures, it is necessary to determine if unilateral stimulation is an effective means of ameliorating PD symptoms. The primary aim of this collaborative project is to determine the effects of unilateral STN DBS on functional upper (manual dexterity) and lower (postural stability and gait initiation) extremity motor performance in Veterans with advanced PD. The results from these studies have the potential to impact the use of DBS in the treatment of advanced PD. Positive bilateral results with unilateral stimulation of STN may allow patients not currently considered eligible for bilateral implantation to be considered for unilateral procedures as a method of treating PD symptoms. Our general hypothesis is that unilateral STN DBS acts to override disrupted neural activity of the basal ganglia in one hemisphere. The resultant normalized basal ganglia output to the SMA then allows for improved planning and control of bilateral actions. Bilateral upper and lower extremity motor performance will be quantified in a group of advanced PD patients with unilateral STN DBS patients while "on" and "off" stimulation. It is hypothesized that unilateral STN DBS will result in bilateral improvements in upper and lower extremity motor function.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date May 2008
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 30 Years to 75 Years
Eligibility Inclusion Criteria:

- a) Patients must have had the Deep Brain Stimulator implanted for at least six months prior to enrollment.

- Hoehn and Yahr stage III or worse when off stimulation and medication

- Intractable, disabling motor fluctuations, dyskinesias or freezing episodes

- Age between 30-75 years

- Normal cognition

- Demonstrated good response to levodopa. In order to exclude patients with Parkinson's plus (i.e. progressive supranuclear palsy, multiple system atrophy, striato-nigral degeneration, etc) all patients included in this study must have demonstrated a good response to levodopa, defined as demonstrating at least 30% improvement in parkinsonian motor signs, based on UPDRS motor examination subscore following the administration of levodopa during their screening neurological exam.

- Unsatisfactory clinical response to maximal medical management A stable and optimal medical regimen of antiparkinsonian drug therapy for at least three months prior to or after surgery

Exclusion Criteria:

- Clinically significant medical disease that would increase risk of developing pre- or postoperative complications (e.g. significant cardiac or pulmonary disease, uncontrolled hypertension).

- Evidence of secondary or atypical parkinsonism as suggested by:

- History of CVA's, exposure to toxins, neuroleptics or encephalitis

- Neurologic signs of upper motor neuron or cerebellar involvement, supranuclear gaze palsy or significant orthostatic hypertension

- Dementia as evidenced by impairment in two neuropsychological domains and impaired or borderline neuropsychological function in one additional domain

- Use of DBS for psychiatric disorder (obsessive compulsive or depression)

Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Device:
Deep Brain Stimulation


Locations

Country Name City State
United States Louis Stoke Cleveland VA Medical Center Cleveland Ohio

Sponsors (1)

Lead Sponsor Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT06037590 - A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops™ Relative to INBRIJA® Phase 1
Recruiting NCT01537224 - Electrophysiological Activity of the Subthalamic Nucleus During the Processing of Emotional and Motivational Information N/A
Withdrawn NCT04011449 - State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With DBS Using the Medtronic RC+S N/A
Completed NCT02539446 - Suprapostural Attention Focus and Postural Difficulty on H-reflex and Brain Activity: Aging and Parkinson's Disease N/A
Active, not recruiting NCT04606979 - tDCS of the Primary Motor Cortex to Improve Implicit Motor Sequence Learning in Parkinson's Disease N/A
Completed NCT05119803 - The Relationship of Spine Posture and Mobility With Upper Extremity Functions in Parkinson's Patients
Recruiting NCT06154772 - Quality of Life, Anxiety and Fatigue Level of Parkison's Patients With Color Therapy N/A
Not yet recruiting NCT02249715 - Development of a Monitoring Set-up and Algorithm Using Functional MRI (fMRI) and EEG for Prediction of Response to Repetitive Deep Transcranial Magnetic Stimulation (rDTMS) for Patients With Parkinson's Disease N/A
Completed NCT01732653 - A Treadmill Training Program Augmented by Virtual Reality to Decrease Fall Risk in Older Adults N/A
Completed NCT03232996 - Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease. N/A
Enrolling by invitation NCT04566341 - Study of Gastrointestinal Dysfunction and Enteric Neural Pathology in Patients With Parkinson's Disease
Active, not recruiting NCT04978597 - Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study) Phase 3
Recruiting NCT06116084 - Randomized Controlled Study Evaluating the Efficacy of Hypnosis in Nuclear Medicine N/A
Recruiting NCT05830396 - GRoningen Early-PD Ambroxol Treatment Phase 2/Phase 3
Not yet recruiting NCT05379062 - Choral Singing for Patients With Parkinson's N/A
Completed NCT02071823 - Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules Phase 1
Recruiting NCT03558568 - The Effect of Deep Brain Stimulation on Facial Expressions. N/A
Enrolling by invitation NCT05596201 - Super-resolution of Brain Magnetic Resonance Images in Deep Brain Stimulation for Parkinson's Disease
Recruiting NCT04181918 - Action Observation Treatment in Parkinson's Patients N/A
Completed NCT02305277 - Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers Phase 1